



















Prostatic Arterial Embolization to Treat Benign
Prostatic Hyperplasia
João M. Pisco, MD, PhD, Luis C. Pinheiro, MD, PhD, Tiago Bilhim, MD,
Marisa Duarte, MD, Jorge R. Mendes, MD, and Antonio G. Oliveira, MD, PhD
ABSTRACT
PURPOSE: To evaluate whether prostatic arterial embolization (PAE) might be a feasible procedure to treat lower urinary tract
symptoms associated with benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: Fifteen patients (age range, 62–82 years; mean age, 74.1 y) with symptomatic BPH after failure
of medical treatment were selected for PAE with nonspherical 200-m polyvinyl alcohol particles. The procedure was performed by
a single femoral approach. Technical success was considered when selective prostatic arterial catheterization and embolization was
achieved on at least one pelvic side.
RESULTS: PAE was technically successful in 14 of the 15 patients (93.3%). There was a mean follow-up of 7.9 months (range, 3–12
months). International Prostate Symptom Score decreased a mean of 6.5 points (P  .005), quality of life improved 1.14 points (P 
.065), International Index of Erectile Function increased 1.7 points (P  .063), and peak urinary flow increased 3.85 mL/sec (P 
.015). There was a mean prostate-specific antigen reduction of 2.27 ng/mL (P  .072) and a mean prostate volume decrease of 26.5
mL (P .0001) by ultrasound and 28.9 mL (P .008) by magnetic resonance imaging. There was one major complication (a 1.5-cm2
ischemic area of the bladder wall) and four clinical failures (28.6%).
CONCLUSIONS: In this small group of patients, PAE was a feasible procedure, with preliminary results and short-term follow-up
suggesting good symptom control without sexual dysfunction in suitable candidates, associated with a reduction in prostate volume.
ABBREVIATIONS
BPH  benign prostatic hyperplasia, IPSS  international prostate symptom score, PAE  prostatic arterial embolization,
PSA  prostate specific antigen, PVA  polyvinyl alcohol, PVR  postvoid residual volume, Qmax  peak urinary flow, QOL
 quality of lifeenign prostatic hyperplasia (BPH) has a high prevalence rate
n men aged 50–79 years (1) and is ubiquitous with aging (2).
PH is a condition often associated with lower urinary tract
ymptoms (3), the most frequent of which are decreased uri-
ary stream, greater frequency, and urgency (4).
Surgery is performed less often now that effective phar-
acotherapy is available, but it is an excellent option for
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patients who develop complications or whose symptoms are
inadequately controlled with medical treatment (5).
Prostatectomy by open surgery or by transurethral re-
section of the prostate is still considered the gold standard
of treatment. Alternative options include minimally inva-
sive treatments and prostatic stent placement. Age, symp-
tom scores, grade of obstruction, baseline prostate volume,
peak urinary flow (Qmax), serum prostate specific antigen
(PSA) value, and postvoid residual volume (PVR) are im-
portant predictors of clinical progression (6) and, along
with individual anesthesiologist risk, are factors that should
be taken into consideration when choosing an appropriate
treatment (7).
Urinary tract infection, strictures, postoperative pain,
incontinence or urinary retention, sexual dysfunction, and
blood loss are complications associated with surgical treat-
ments. Minimally invasive treatments were originally con-
ceived as an attempt to offer equivalent efficacy without the
burden and risk of operative morbidity. However, they have



















































12  Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Pisco et al  JVIRymptom scores (8), greater risk of continued catheteriza-
ion and reoperation, and poorer durability of symptomatic
enefit (9).
There is the need for innovative technologies to con-
inue to improve outcomes and minimize patient discomfort
nd morbidity when managing BPH (10). Recently, it was
uggested that prostatic arterial embolization (PAE) to treat
PH might follow uterine artery embolization for uterine
eiomyomas (11). Animal studies in pigs and dogs have
hown that PAE is safe, with no related sexual dysfunction,
nd can induce prostatic volume reduction (12,13). The first
eport of this technique in the management of BPH in
umans was by DeMeritt et al (14), who reported a single
ase of BPH with obstructive symptoms and blood loss
efractory to other treatments that was successfully man-
ged by PAE with 150–250-m polyvinyl alcohol (PVA)
articles. More recently there has been a report of two other
atients in similar clinical scenarios treated with success
ith the use of 300–500-m microspheres (15).
We investigated whether PAE might be a feasible
rocedure as an alternative treatment option to treat BPH-
ssociated symptoms while preserving sexual function. For
his purpose, we report preliminary results in 15 patients
ho underwent PAE with PVA particles as the treatment
ption in the management of complicated BPH or BPH
efractory to medical therapy.
ATERIALS AND METHODS
tudy Population
prospective study was undertaken from March 2009 to
pril 2010 in 15 patients aged 62–82 years (mean, 74.1 y)
ho presented with symptomatic BPH refractory to medi-
al treatment for at least 6 months (mean International
rostate Symptom Score [IPSS], 21) with a clinical indica-
ion for surgery who agreed to undergo PAE. The study was
pproved by the hospital ethical committee and an informed
onsent form for PAE as an alternative treatment was
igned by all participants. Study criteria included male
atients with age greater than 60 years and a diagnosis of
PH with moderate to severe lower urinary tract symptoms
ie, IPSS  18) refractory to medical treatment for at least
months, sexual dysfunction or accepting the risk of de-
eloping sexual dysfunction after treatment, and/or Qmax
ower than 12 mL/s or acute urinary retention. Malignancy
evaluated by PSA, physical examination, transrectal ultra-
ound [US], and magnetic resonance [MR] imaging in all
atients and by prostatic biopsy in suspicious cases) and
dvanced atherosclerosis and tortuosity of iliac arteries
based on visual evaluation by the interventional radiolo-
ists of pelvic MR angiography performed before PAE in
ll patients) were exclusion criteria. Patients with minimal
o moderate lower urinary tract symptoms were also con-
idered for PAE if Qmax was lower than 12 mL/s if thepatients were unsatisfied with the results of medical therapy
or had urinary retention.
The patients were not randomized. PAE was not pro-
posed when surgery was indicated for other reasons (eg,
secondary renal insufficiency as a result of prostatic ob-
struction, hematuria, bladder diverticula, or stones).
All patients were informed about the embolization
technique used, and the experimental nature was clearly
indicated. The patients were allowed to choose freely
among PAE, transurethral resection of the prostate/open
surgery, or laser surgery. During this time period, 98 pa-
tients met the inclusion criteria, of whom 57 opted for
transurethral resection/open surgery, 18 for laser surgery,
and 23 for PAE. Eight patients were excluded as a result of
malignancy in two and advanced atherosclerosis and tortu-
osity of iliac arteries in six.
All patients were undergoing medical therapy with
symptoms that persisted for more than 6 months. Medical
therapy was consistent among patients, with each receiving
one -1-adrenergic receptor antagonist (alfuzosin 10 mg,
doxazosin 4 mg, or tamsulosin 0.4 mg once daily). One
patient had a partial prostatectomy 14 years before and six
had bladder catheters at the time as a result of acute urinary
retention.
Pelvic MR angiography with a 1.5-T system (Philips,
Eindhoven, The Netherlands) was performed before PAE to
evaluate the pelvic vessels for tortuosity and atherosclerotic
changes of the iliac arteries. All patients were evaluated by
clinical observation with measurement of the IPSS and
quality of life (QOL)–related symptoms (score from 0,
“delighted”; to 6, “terrible”), sexual function tests (Interna-
tional Index of Erectile Function; score from 0 to 30),
uroflowmetry (Qmax and PVR), PSA level, and transrectal
US to calculate prostatic volume. Baseline data were ob-
tained before PAE and the response to treatment was mea-
sured at 1, 3, and 6 months after the procedure. The prostate
volume was also measured by MR before and 6 months
after PAE (Fig 1).
The prostate diameters were visually measured by tran-
srectal US and MR on the three plane axes: sagittal, ceph-
alocaudal, and transverse. Volumes were assessed with the
ellipsoid formula: /6  (transverse diameter  anteropos-
terior diameter  cephalocaudal diameter). One observer
performed all transrectal US examinations and another all
MR examinations (two experienced radiologists) with the
use of these measurement techniques and volume formulas
before and after PAE to avoid interobserver variability.
Prostatic biopsy was performed in all cases of sus-
pected prostatic malignancy based on PSA level greater
than 4 ng/mL or suspicious focal lesions detected on tran-
srectal US or MR. All cases positive for malignancy were
excluded.
Embolization Technique
The patients stopped all prostatic medication 1 week before
embolization, and after successful PAE, all prostatic med-

























Volume 22  Number 1  January  2011 13rug (omeprazole 20 mg once daily), and an antiinflamma-
ory agent (naproxen 1,000 mg twice daily) for 2 days
efore the procedure and continued to receive them for 10
ays after PAE. The day of PAE, patients received ome-
razole 20 mg and naproxen 1,000 mg in the morning
efore PAE and naproxen 1,000 mg as postembolization
edication 8 hours after PAE. The patients were admitted
o the hospital on the day of the procedure. During embo-
ization, analgesic and antiinflammatory drugs were given
ntravenously (ketorolac 30 mg and metamizole 2 g intra-
enously). Embolization was performed under local anes-
hesia by unilateral approach, usually the right femoral
rtery. Initially, pelvic angiography was performed to eval-
ate the iliac and prostatic arteries. Then, a 5-F Cobra-
haped catheter (Cordis, Warren, New Jersey) was intro-
uced in right femoral artery to catheterize the left
ypogastric artery and reach its anterior division. The in-
erior vesical artery and finally the prostatic vessels were
igure 1. Pelvic MR images in a 78-year-old patient with BPH
iameter of 59.2 mm and a prostate volume of 95.5 mL. (b) Axia
f 49.9  61.8 mm and prostate volume of 95.5 mL. (c) Sagittal
f 40.2 mm and prostate volume of 36.6 mL, a decrease of 61.
ransverse diameters of 39.0  44.7 mm and prostate volume oelectively catheterized with a 3-F coaxial microcatheter(Progreat; Terumo, Tokyo, Japan). Another angiography
study was performed to confirm the position of the catheter
in the ostium of the prostatic artery before embolization.
For embolization, nonspherical 200-m PVA particles
(Cook, Bloomington, Indiana) were used. The endpoint
chosen for embolization was slow flow or near-stasis in the
prostatic vessels with interruption of the arterial flow and
prostatic gland opacification. When embolization of the
left prostatic arteries was finished, a Waltman curve was
formed on the Cobra catheter and the right prostatic arteries
were embolized in the same way (Fig 2). The PAE proce-
dure time was measured starting with femoral puncture
access and ending after removal of the catheter after PAE.
Fluoroscopy time was also recorded. Pain assessment was
performed during PAE and in the 6–8 hours afterward by
verbal questioning and written questionnaires with a visual
analog scale. Patients were asked to rate their pain severity
from 0 (sensation of no pain) to 10 (the worst pain imag-
agittal pelvic MR before PAE shows a prostate cephalocaudal
e before PAE shows prostate sagittal and transverse diameters
6 months after PAE shows a prostate cephalocaudal diameter
) Axial image 6 months after PAE shows prostate sagittal and



























14  Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Pisco et al  JVIRSymptoms of postembolization syndrome including
ain and fever were not considered complications unless
ain and/or fever resulted in prolonged hospitalization or
ospital readmission. Postprocedural fever was qualified as
complication when a detailed history, physical examina-
ion, and laboratory evaluations confirmed a specific etiol-
gy. Complications were categorized as complications of
ngiography (related to puncture site, contrast agents, or
adiation injury), pelvic infection, ischemic complications,
exual dysfunction, nonprostatic embolization, adverse
rug reactions, pulmonary embolism, and other. Complica-
ions were considered minor if they could be addressed by
mbulatory medical treatment and major if they resulted in
rolonged hospitalization or hospital readmission and/or
eed for surgery.
efinitions and Outcomes Measures
he IPSS is a validated questionnaire that is a simple and
igure 2. Angiographic findings in a 74-year-old patient with ur
arrow, a) and after (b) embolization (arrow). (c) After embol
ngiography, the prostate is slightly opacified (arrow). The bladd
arrow, d) and after (e) embolization (arrow). Left internal pude
eft prostatic arteries, in the parenchymal phase of angiography
atheter is marked with an arrowhead.eliable method to assess the presence, type, and severity ofsymptoms and the response to treatment (Fig 3) (16). The
questionnaire yields a total score ranging from 0 to 35 (1–7
for mild symptoms, 8–19 for moderate, and 20–35 for
severe). One additional question (about how men feel about
their current urinary symptoms) yields a score for QOL (0,
delighted; 6, terrible). The response on the QOL question is
a strong predictor for patient management. Objective mea-
surement of uroflowmetry variables such as Qmax and PVR
gives useful information on micturition, and the results can
be used to assess severity of obstruction and predict the
likelihood of disease progression and response to treatment
(17). The normal Qmax in a young healthy adult male
subject is approximately 25 mL/sec, whereas the Qmax in a
patient with BPH reflects a weaker stream and is more
stable as a result of urethral compression (Fig 4) (16).
When the Qmax measured by uroflowmetry is lower than 12
mL/sec, generally it is indicative of BPH.
Sexual dysfunction is frequently associated with BPH
retention with a bladder catheter. Right prostatic arteries before
of the right prostatic arteries, in the parenchymal phase of
eter is marked with an arrowhead. Left prostatic arteries before
rtery remains patent (arrowhead). (f) After embolization of the
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Volume 22  Number 1  January  2011 15function can be assessed with the International Index of
Erectile Function, a widely used, multidimensional self-
reporting instrument that has been recommended as a pri-
mary endpoint for clinical trials and for diagnostic evalua-
tion of erectile dysfunction severity (18).
Technical success was considered when selective pros-
tatic arterial catheterization and embolization was achieved
at least on one pelvic side.
Cases of persisting severe symptoms (ie, IPSS  20)
and/or Qmax of 7 mL/sec or lower after PAE were consid-
ered clinical failures. Possible ischemic, infectious, or
puncture site complications were evaluated by clinical and
physical examination with pain assessment the day after
PAE and weekly in the following months. Further imaging
or laboratory studies were used when a complication was
suspected. Clinical success was based on intent to treat and
atic hyperplasia in primary care: what you need to know. J Uroligure 4. BPH effects on urinary flow. Q is urinary flow rate in
L/sec. BPO is benign prostatic obstruction. Adapted from Bur-
ett AL, Wein AJ. Benign prostatic hyperplasia in primary care:
































16  Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Pisco et al  JVIRcore  20) and/or improvement of Qmax to greater than 7
L/sec after PAE.
tatistical Analysis
or comparisons of baseline and outcome variables, the
aired t test and Shapiro-Wilk test were used. Stata soft-
are (release 10; Stata, College Station, Texas) was used
or all statistical analyses. Statistically significant differ-
nces were assumed at a P value lower than .05.
ESULTS
ine patients underwent prostatic biopsy in view of high
SA levels ( 4 ng/mL) to exclude malignancy. All biopsy
ndings were negative for neoplasia.
PAE was technically successful in 14 of the 15 patients
93.3%). In one patient (6.7%), the procedure was impos-
ible as a result of tortuosity and atherosclerotic changes of
he iliac arteries; surgery was required in this case. We
erformed PAE bilaterally in 13 patients (technical success
ate for bilateral PAE, 86.7%) and unilaterally in one pa-
ient (patient 11) as a result of tortuosity and atherosclerotic
hanges of the iliac arteries. In these two patients with
ortuosity and atherosclerotic changes of the iliac arteries
onsidered for PAE, pelvic MR angiography showed com-
on and external iliac artery patency without significant
therosclerotic changes, without defining the extent of ath-
rosclerosis in the internal iliac arteries inside the pelvis.
The PAE procedure lasted between 25 and 135 minutes
mean, 85 min) and fluoroscopy time ranged between 15
nd 45 minutes (mean, 35 min). Mean follow-up was 7.9
onths (range, 3–12 months). Only one vial of 200-m
VA particles was used in each patient.
Six patients had urinary retention with vesical cathe-
ers. Only one patient (patient 10) felt pain during emboli-
ation; no other patient experienced pain during or after the






IPSS 8 21.0  8.38
QOL 7 3.86  1.07
IIEF 14 16.2  9.42
PSA (ng/mL) 14 8.76  6.69
Qmax (mL/sec) 8 7.06  2.63
Prostate volume (mL)
On US 14 97.4  27.0
On MR 9 104.9  36.3
PVR (mL) 8 130.8  30.8
Note.—IIEF  International Index of Erectile Function.
* Values presented as means  SD.
† Values presented as means  SEM.rocedure. Twelve patients were discharged from the hos-pital 6–8 hours after the procedure (ie, outpatients) and the
remaining three patients were discharged 18 hours after (the
next morning; ie, inpatients). Vesical catheters were re-
moved 5 days after the procedure in four patients and 10
days after PAE in the remaining three.
Baseline data of the 14 treated patients are shown in
Table 1. Before PAE, the mean IPSS score was 21  8.38,
the mean QOL score was 3.86  1.07, the mean sexual
function score was 16.2  9.42, the mean PSA was 8.76
ng/mL 6.69, the mean Qmax was 7.06 mL/sec 2.63, and
the mean PVR was 130.8 mL  30.8. The mean baseline
prostate volumes were 97.4 mL  27.0 calculated by US
and 104.9 mL  36.3 calculated by MR.
One month after PAE, without any prostatic medica-
tion, there was a mean reduction of the IPSS of 6.7 points,
of the QOL score of 1 point (indicating an improvement),
and of the mean sexual function score of 0.9 points. The
mean Qmax increased 1.6 points, the mean PSA decreased
25.8%, and there was a mean prostate volume reduction of
22%. The stability of the results was confirmed on subse-
quent examinations. Follow-up at 1 and 3 months was
possible in all patients; follow-up at 6 months was possible
in nine patients (Table 2). One patient with colon carci-
noma and lung metastases died at 3 months after PAE. The
remaining four patients are currently doing well and await
follow-up examination at 6 and 12 months.
At the last follow-up—at 3 months (in five patients)
and 6 months (in nine patients)—there was a mean decrease
in the IPSS of 6.5 points (P  .005), a mean improvement
in QOL (ie, score reduction) of 1.14 points (P  .065), and
a mean increase in the sexual function score of 1.71 points
(P  .063). There was a mean PSA reduction of 2.27
ng/mL (P  .072), a mean Qmax increase of 3.85 mL/sec
(P  .015), and a mean prostate volume decrease of 26.5
mL on US (P  .0001) and 28.9 mL on MR (P  .008).
There was a PVR reduction of 79.5 mL (P  .0004).
Minor complications were seen in two patients with
tment
ent*
Mean Difference† P ValueLast Follow-up
14.5  8.00 6.5  1.58 .005
2.71  1.38 1.14  0.51 .065
17.9  8.77 1.71  0.84 .063
6.49  6.73 2.27  1.16 .072
10.91  5.34 3.85  1.21 .015
70.9  24.3 26.5  4.62 .0001
76.0  27.9 28.9  8.28 .008
51.3  21.8 79.5  12.4 .0004r Trea




























Volume 22  Number 1  January  2011 17ibiotics and one patient with acute urinary retention after
AE (patient 10). For relief, a bladder catheter was placed
t the time. A major complications was seen in one case
7.1%) of a small area (1.5 cm2) of bladder wall ischemia in
he right side of the base without involvement of the ure-
eral or urethral orifices (the same patient with intraproce-
ural pain; patient 10). The area of ischemia at the bladder
ase was removed by surgery without further complica-
ions.
There were four cases (28.6%) that were considered
linical failures (patients 3, 4, 10, and 12). Two had per-
isting severe symptoms after PAE (IPSS persisted  20 in
atients 4 and 10) and all had a Qmax no greater than 7
L/s.
Patient 10 required further surgery to treat the area of
schemia at the bladder base and had persisting prostatic
ymptoms. However, all remaining patients were doing
ell at the time of last follow-up, stopped all prostatic
edication, and reported no sexual dysfunction. There was
o need for prostatic surgery after PAE in any other case.
ISCUSSION
xperimental animal studies in pigs and dogs have shown
hat PAE can induce prostatic volume reduction and that it
s safe, with no associated sexual dysfunction (12,13). Pros-
atic embolization to control severe hemorrhage has also
een successfully performed in human subjects in different
ase series (19,20). Also, case reports in human subjects
ave shown that PAE is safe and can induce prostate
Table 2. Changes at Last Control Follow-up of Prostatic Arter
Pt. No/
Age (y)
IPSS QoL IIEF PSA (ng/m
Before After Before After Before After Before Aft
1/76 TCD 3 TCD 1 17 20 15 3.
2/74 16 14 3 3 6 11 3.9 4.
3/78 26 17 5 4 28 28 24 15.
4/78 33 26 5 4 2 4 3.12 2.
5/76 TCD 4 TCD 1 15 15 8.6 6.
6/74 22 7 4 1 13 22 2.29 2.
7/72 TCD 11 TCD 3 15 15 3.17 1.
8/77 8 6 2 1 15 14 5.1 2.
9/71 TCD 5 TCD 2 24 24 9.3 8.
10/70 29 26 4 4 27 27 3.21 4.
11/73 13 8 2 2 12 19 11.01 9
12/62 TCD 19 TCD 3 30 30 20 26
13/82 21 12 4 1 23 22 6.9 1.
14/74 TCD 5 TCD 1 0 0 7.04 3.
Note.—IIEF  International Index of Erectile Function; TCD 
* Patient died.olume reduction and relief of obstruction-related voidingsymptoms (14,15). In the present study, we report the
preliminary results of prostatic embolization for BPH-re-
lated symptoms in a small series of human patients.
In the study by DeMeritt et al (14), the IPSS decreased
from 24 to 13 after 1 year, the prostatic volume was reduced
by 40% at 5 and 12 months, and the PSA level decreased
from 40 ng/mL to 4 ng/mL (ie, 90% reduction). There was
no sexual dysfunction after the treatment (14). In this study,
unilateral embolization was performed with a good out-
come.
Prostate size may not be related to obstruction severity,
so unilateral embolization may achieve enough organ isch-
emia to allow symptom improvement, even with lower
volume reduction. It may be possible that, unlike uterine
artery embolization, PAE might be successful only with
unilateral embolization—the criteria chosen in the present
study for technical success.
In the study by Carnevale et al (15), one of the patients
underwent embolization on one side, with 27.8% prostate
volume reduction, and the other patient underwent embo-
lization on both sides, with a 47.8% volume decrease at 6
months. However, in this study (15), clinical evaluation of
IPSS, QOL, sexual function, PSA, Qmax, and PVR was not
performed.
In the present study, despite the withdrawal of all
prostatic medications after PAE, there was a significant
improvement of the IPSS (mean improvement of 6.5 points;
range, 2–16 points). QOL improved in all but three patients
whose QOL remained stable (patients 2, 10, and 11). The










up (mo)ore After Before After Before After Before After
D 15.2 91 32 95 37 TCD 23 12
.2 8.2 122 93 132 94 160 60 11
.6 6.4 143 120 185 124 97 40 10
.7 6.9 59 45 60 185 54 3*
D 24.2 118 86 107 52 TCD 15 9
16.7 61 41 58 42 103 41 9
D 9.5 96 74 98 82 TCD 14 9
.2 20.5 120 83 98 80 121 37 9
D 8.5 76 67 74 80 TCD 52 9
.1 5.0 96 94 97 93 106 56 9
.1 12.5 64 59 76 — 129 97 5
D 4 121 85 112 — TCD 31 5
.6 11.1 77 52 78 — 145 25 5
D 12.3 119 61 119 — TCD 78 5





































































18  Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Pisco et al  JVIRlinically insignificant). The improvement of erectile func-
ion might be explained by the discontinuation of all pros-
atic medication after PAE, although these results were not
tatistically significant. There was a tendency for PSA
eduction in almost all cases. There were four patients with
nsignificant increases in PSA (patients 2, 6, 10, and 12, the
atter related to prostatic biopsy). There was a significant
mprovement in Qmax (mean improvement of 3.85 mL/sec;
ange, 9.3–1.2 mL/sec). There was a significant prostate
olume reduction in all patients (mean reduction, 26.5–28.9
L; range, 7.8%–64.8%, the former reduction in a patient
ith unilateral PAE). PVR decreased significantly in all
atients.
Despite the general improvement in most parameters
valuated, there were four clinical failures (28.6%) with
ersisting severe symptomatology after PAE (ie, IPSS 20
oints) or Qmax remaining lower than 7 mL/sec after PAE.
ost of these patients had severe symptoms before PAE
espite prostatic medical therapy and had partial relief after
AE without the need for further prostatic medication.
espite the persisting symptoms, three patients are cur-
ently doing well without the need for prostatic medication
r surgery. One patient (patient 10) required surgery for
rostatic symptomatic relief and removal of a small area of
schemia at the bladder base.
Minor IPSS improvements (ie,  3 points) after PAE
ere observed in two patients (patients 2 and 8) and were not
onsidered clinical failures because both patients remained
ith acceptable moderate-to-low IPSS score after PAE despite
eceiving no prostatic medication. Also, both patients showed
n improvement in Qmax to greater than 7 mL/sec.
The lowest reduction of prostate volume and PVR after
AE occurred in patient 10 (the patient with bladder ne-
rosis) and patient 11 (the patient who underwent unilateral
mbolization). Because of the intraprocedural pain caused
y bladder necrosis in patient 10, an incomplete emboliza-
ion was performed.
It is interesting to note that patient 11, who underwent
nilateral embolization, had only a 7.8% prostatic volume
eduction. Even so, his IPSS score improved five points
from 13 to 8) and his Qmax almost doubled (increase of 6.4
L/sec from 6.1 to 12.5 mL/sec). Also, we found a poor
orrelation between prostatic volume reduction and clinical
utcome. These results may imply that prostatic volume
eduction might not be the only mechanism that allows
ymptom improvement after PAE, as it is also noted that
here is a weak correlation between prostate size and lower
rinary tract symptoms. Further studies are warranted to
onfirm this hypothesis.
Pelvic MR angiography was performed in all patients
o exclude patients with extensive arterial occlusive disease.
ge range and male sex are important risk factors associ-
ted with BPH and atherosclerotic changes that may pose a
ontraindication to the procedure.
In contrast to uterine artery embolization, we noted
inimal postembolization symptoms in our study patients.
he antiinflammatory drugs used before, during, and afterPAE may be enough to prevent possible embolization-
related symptoms. Only one patient (patient 10) felt intra-
procedural pain, and this patient later developed a small
area of bladder wall ischemia. The fact that a more exten-
sive embolization of the bladder vessels was performed in
this patient because the prostatic arteries had a proximal
origin near the branches of the inferior vesical artery might
explain the complication. After surgical removal of the
1.5-cm2 zone of ischemia of the bladder wall, the patient’s
symptoms improved. There were no cases of nausea or
vomiting. All patients who underwent PAE (except patient
10) were doing well at the time of last follow-up, with
stable or with some improvement in sexual function, with-
out any prostate-specific medication or need for prostate
surgery. The preservation of sexual function and the mini-
mally invasive and nonsurgical nature of this procedure are
great advantages.
The present study has some limitations. We were not
able to measure the IPSS, QOL, and Qmax in the six patients
who underwent transurethral catheter drainage before PAE.
Therefore, the mean IPSS, QOL, and Qmax before PAE
were based on eight patients, and only changes from base-
line could be evaluated in these patients. Also, there were no
pressure-flow urodynamics performed, there was no placebo
or comparator arm, there was a short follow-up period, and the
study was not randomized. The endpoint follow-up period in
the group was not the same for all patients and it was not
possible to assess the time to maximal effects, size reduction,
and possible time to recurrence.
This study did not intend to compare PAE with pla-
cebo, medical therapies, or surgery, so it is not possible to
imply if these clinical results after PAE could be compara-
ble to placebo or medical therapy mainly because these
were all patients who were receiving prostatic medication
and stopped all medication after the procedure, with good
outcomes. There is some evidence that other factors besides
prostatic volume reduction may account for clinical out-
comes after PAE. Further studies are warranted to confirm
this hypothesis and to compare PAE with placebo and
medical and surgical therapies.
Although the results are preliminary with a small num-
ber of patients and a short follow-up period, they are very
promising. More studies are needed with greater numbers
of patients, different sizes of PVA particles, and longer
follow-up to asses if the procedure can be an effective and
a safe alternative in the management of BPH.
We conclude that PAE is a feasible procedure, with
preliminary results and short-term follow-up suggesting good
symptom control without sexual dysfunction in suitable can-
didates, associated with a reduction in prostate volume.
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